To order a free Chaikin Power Gauge stock research report for ONXX go to http://www.chaikinpowertools.com/reports

1. Onyx Pharma Inc (ONXX) Price: $31.75
Industry: Drugs
Chaikin Power Gauge Report | Generated: Thu Sep 22 16:08 EDT 2011
ONXX
Onyx Pharma Inc $31.75 Power Gauge Rating
ONXX - Very Bearish
TM
The Chaikin Power Gauge Rating for ONXX is very bearish due to very poor
financial metrics, weak earnings performance and negative expert opinions.
The rating also reflects bullish price/volume activity.
Financial Metrics
ONXX's financial metrics are very poor due to a low return on equity.
Earnings Performance
ONXX's earnings performance is weak as a result of worse than expected
Price/Volume Activity
earnings in recent quarters.
Expert Opinions
News Sentiment Rating
Neutral
ONXX Onyx Pharma .. September 09, 2011 TM
Chaikin Sentiment Gauge for ONXX is neutral. Stories concerning ONXX
have a balanced or neutral sentiment.
News Sentiment :Neutral
Power Trend - 5 Year Chart
The Power Gauge distills a 20 factor model into a concise picture of a stock's potential. High Potential Neutral Low Potential
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here www.chaikinpowertools.com

2. Financials & Earnings
Financial Metrics
Financial Metrics Rating
LT Debt/Equity Ratio
Very Bearish
Price to Book Value ONXX's financial metrics are very poor. The company yields a relatively low
return on shareholder's equity and is carrying too much long term debt.
Return on Equity
The rank is based on a high long term debt to equity ratio, high price to book
value ratio and low return on equity.
Price to Sales Ratio
Business Value
Assets and Liabilities Valuation Returns
Ratio TTM Ratio TTM Ratio TTM
Current Ratio 12.30 Price/Book 3.24 Return on Invest -3.4%
LT Debt/Equity 0.22 Price/Sales 6.22 Return on Equity -4.2%
Earnings Performance
Earnings Performance Rating
Earnings Growth
Bearish
Earnings Surprise ONXX's earnings performance has been weak. The company has not met
analysts' earnings estimates and has a history of weak earnings growth.
Earnings Trend The rank is based on worse than expected earnings in recent quarters and
consistent earnings over the past 5 years.
Projected P/E Ratio
Earnings Consistency
5 Year Revenue and Earnings Growth EPS Estimates
12/06 12/07 12/08 12/09 12/10 Factor Actual EPS Prev EST EPS Current Change
Revenue(M) 0.25 - 194.34 251.39 324.52 Quarterly EPS $0.66 $-0.32 -0.98
Rev % Growth -75.00% - - 29.35% 29.09% Yearly EPS $-1.35 $-1.76 -0.41
EPS $-2.20 $-0.67 $0.03 $0.27 $-1.35 Factor Actual EPS Growth Est EPS Growth Change
EPS % Growth 16.67% 69.55% 104.48% 800.00% -600.00% 3-5 year EPS -5.52% 43.00% +48.52
EPS Surprise EPS Quarterly Results
Estimate Actual Difference % Difference FY Qtr 1 Qtr 2 Qtr 3 Qtr 4 Total
Latest Qtr $-0.34 $-0.43 $-0.09 -26.47 12/09 $0.07 $0.16 $0.14 $-0.09 $0.28
1 Qtr Ago $-0.29 $-0.31 $-0.02 -6.90 12/10 $-0.19 $-1.55 $0.66 $-0.27 $-1.35
2 Qtr Ago $-0.11 $-0.36 $-0.25 -227.27 12/11 $-0.78 $-0.86 - - -
3 Qtr Ago $-0.04 $0.66 $0.70 1750.00 Fiscal Year End Month is December.
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here www.chaikinpowertools.com

3. Price Trend & Expert Opinions
Price/Volume Activity
Price/Volume Activity Rating
Relative Strength vs Market Bullish
Chaikin Money Flow
Price and volume activity for ONXX is bullish. ONXX has outperformed the S&P
500 over 26 weeks and is experiencing sustained buying.
Price Trend
The rank for ONXX is based on its price strength versus the market, positive
Price Trend ROC
Chaikin money flow, a positive Chaikin price trend and a decreasing volume
trend.
Volume Trend
Relative Strength vs S&P500 Index Chaikin Money Flow
Chart shows whether ONXX is performing better or worse than the market. Chaikin Money Flow analyzes supply and demand for a company's stock.
Price Activity Price Activity Volume Activity
Factor Value Factor Value Factor Value
52 Week High 45.37 % Change Price - 4 Weeks 0.00% Average Volume 20 Days 694,041
52 Week Low 25.53 % Change Price - 24 Weeks -6.59% Average Volume 90 Days 863,598
% Change YTD Rel S&P 500 -8.33% % Change Price - 4 Wks Rel to S&P 0.93% Chaikin Money Flow Persistency 58%
% Change Price - 24 Wks Rel to S&P 6.92%
Expert Opinions
Expert Opinions
Earnings Estimate Revisions Bearish
Short Interest Expert opinions about ONXX are negative. Analysts are lowering their EPS
estimates for ONXX and short interest in ONXX is high.
Insider Activity
The rank for ONXX is based on analysts revising earnings estimates downward, a
high short interest ratio, insiders purchasing stock, optimistic analyst opinions and
Analyst Opinions
price strength of the stock versus the Drugs industry group.
Relative Strength vs Industry
Earnings Estimate Revisions Analyst Recommendations EPS Estimates Revision Summary
Current 7 Days Ago % Change Factor Value Last Week Last 4 Weeks
Current Qtr -0.32 -0.32 0.00% Mean this Week Buy Up Down Up Down
Next Qtr -0.56 -0.56 0.00% Mean Last Week Buy Curr Qtr 0 0 0 0
Curr Yr 0 0 1 0
Current 30 Days Ago % Change Change -0.06
Next Qtr 0 0 0 0
Current FY -1.76 -1.94 0.18 Mean 5 Weeks Ago Buy
Next Yr 0 0 0 0
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here www.chaikinpowertools.com

4. The Company & Its Competitors
ONXX's Competitors in Drugs News Headlines for ONXX
Company Power Historic EPS Projected EPS Profit Margin PEG PE Revenue(M) Pfizer files for US approval of kidney cancer
Gauge growth growth drug - Jun 28, 2011
ONXX -5.52% 43.00% -24.19% - - 325 Onyx Pharmaceuticals Receives Fast Track
FRX 9.84% -2.00% 26.36% -4.20 6.98 4,420
Designation for Carfilzomib; Company Initiates
Rolling NDA Submission for Accelerated
WCRX 45.93% 10.78% 4.28% 0.38 4.20 2,974 Approval - Jan 31, 2011
ENDP 15.95% 13.22% 12.13% 0.46 7.08 1,716 Apricus, FDA agree on liver cancer drug study -
Nov 22, 2010
SHPGY 17.38% 15.68% 17.66% 1.13 19.71 3,471
SBIO JAK2 Inhibitor 10 18 - Oct 18, 2010
ELN 19.58% - -6.04% - - 1,170
Onyx Pharmaceuticals Provides Status Update
VRX 7.07% 16.53% -9.29% 0.86 27.07 1,181
on Carfilzomib - Oct 7, 2010
Company Details Company Profile
ONYX PHARMA INC Onyx Pharmaceuticals, Inc is developing innovative products for the treatment of cancer.
249 E. GRAND AVE.
SOUTH SAN FRANCISCO, CA
94080
USA
Phone: 650-266-0000
Fax: 650-266-0100
Website: http://http://www.onyx-
pharm.com/
Full Time Employees: 299
Sector: Medical
Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculated
by evaluating each of the stocks factors and combining them into a single number using a weighting formula. A stock's rank ranges from 100-0, where 100 is the
strongest, and a rank of 95 indicates the stock is better than 95% of the stocks in the universe.
Chaikin Stock Research(CSR) is not registered as a securities broker dealer or investment advisor with either the U.S. Securities and Exchange Commission or with any
state securities regulatory authority. CSR is not responsible for trades executed by users of this research report, our web site or mobile app based on the information
included herein. The information presented in this report does not represent a recommendation to buy or sell stocks or any financial instrument nor is it intended as an
endorsement of any security or investment. The information in this report is generic by nature and is not personalized to the specific financial situation of any individual.
The user bears complete responsibility for their own investment research and should seek the advice of a qualified investment professional before making any investment
decisions.
Copyright (c) 1978-(Present) by ZACKS Investment Research, Inc ("ZACKS"). The information, data, analyses and opinions contained herein (1) includes the
confidential and proprietary information of ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by
ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be
responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no
guarantee of future performance. ZACKS is not affiliated with Chaikin Power Tools.
This report from Chaikin Power Tools is for informational purposes only and is not a recommendation to buy or sell securities.
LM 2.3 DS 3.0 LS 2.1
Data Provided by ZACKS Investment Research, Inc., www.zacks.com Special offers to trade stocks from optionsXpress: www.chaikinpowertools.com